Featuring an interview with Prof Martin Reck, including the following topics:

• Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00)
• Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25)
• Considerations with maintenance therapy for ES-SCLC (9:31)
• Considerations with immunotherapy for ES-SCLC (13:12)
• Curability of SCLC with systemic therapy (15:17)
• Data with chemoimmunotherapy for patients with poor performance status (25:55)
• Future developments in therapy for SCLC (30:11)
• Rapid fire: Small Cell 101 (35:45)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics:

• Introduction (0:00)
• Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)
• Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41)

CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O’Malley and Dr Brian M Slomovitz, moderated by Dr O’Malley, including the following topics:

• Introduction (0:00)
• Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Liu (2:52)
• Available Data with and Practical Application of HER2-Targeted Therapy in Advanced Gynecologic Cancers — Dr Slomovitz (25:16)
• Identification and Management of Adverse Events with Trastuzumab Deruxtecan — Dr O’Malley (1:00:31)

CME information and select publications

Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:

• Introduction (0:00)
• Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)
• Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14)

CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics:

• Introduction (0:00)
• Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12)
• Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54)
• Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49)
• Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12)
• Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26)

CME information and select publications

Featuring perspectives from Dr Eileen M O’Reilly and Dr Philip A Philip, including the following topics:

• Introduction (0:00)
• Optimal Incorporation of Chemotherapy into the Management of Advanced Pancreatic Cancer — Dr Philip (7:27)
• Other Available and Emerging Novel Approaches for Pancreatic Cancer — Dr O’Reilly (28:05)

CME information and select publications

Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:

• Introduction (0:00)
• Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05)
• Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21)
• Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12)
• CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof Salles (1:08:33)
• Other Approved and Emerging Novel Therapies for FL — Dr Patel (1:24:44)
• Integrating Bispecific Antibodies into the Management of FL — Dr Kamdar (1:41:34)

CME information and select publications

Dr Thomas Hutson from the Sarah Cannon Research Institute in Abilene, Texas, Dr Eric A Singer from The Ohio State University Comprehensive Cancer Center in Columbus and Dr Ulka Vaishampayan from the University of Michigan Health Rogel Cancer Center in Ann Arbor discuss recent data surrounding the management of localized renal cell carcinoma and share their perspectives on the clinical application.

CME information and select publications